These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18813015)

  • 1. Data analysis methods and the reliability of analytic epidemiologic research.
    Prentice RL
    Epidemiology; 2008 Nov; 19(6):785-8; discussion 789-93. PubMed ID: 18813015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?
    Roy JA; Sawka CA; Pritchard KI
    J Clin Oncol; 1996 Mar; 14(3):997-1006. PubMed ID: 8622051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term hormone therapy for perimenopausal and postmenopausal women.
    Marjoribanks J; Farquhar C; Roberts H; Lethaby A
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal hormone therapy in clinical perspective.
    Hodis HN; Mack WJ
    Menopause; 2007; 14(5):944-57. PubMed ID: 17353803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
    van de Weijer PH; Mattsson LA; Ylikorkala O
    Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for use of lower estrogen doses for postmenopausal hormone therapy.
    Ettinger B
    Maturitas; 2007 May; 57(1):81-4. PubMed ID: 17383126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy in clinical perspective.
    Dören M; Greiser EM
    Menopause; 2008; 15(1):204-5; author reply 205. PubMed ID: 18257150
    [No Abstract]   [Full Text] [Related]  

  • 12. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment.
    Chlebowski RT; Anderson GL
    J Natl Cancer Inst; 2011 Feb; 103(4):284-5. PubMed ID: 21278357
    [No Abstract]   [Full Text] [Related]  

  • 14. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.
    Asi N; Mohammed K; Haydour Q; Gionfriddo MR; Vargas OL; Prokop LJ; Faubion SS; Murad MH
    Syst Rev; 2016 Jul; 5(1):121. PubMed ID: 27456847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.
    Nabulsi AA; Folsom AR; White A; Patsch W; Heiss G; Wu KK; Szklo M
    N Engl J Med; 1993 Apr; 328(15):1069-75. PubMed ID: 8384316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis.
    Benkhadra K; Mohammed K; Al Nofal A; Carranza Leon BG; Alahdab F; Faubion S; Montori VM; Abu Dabrh AM; Zúñiga Hernández JA; Prokop LJ; Murad MH
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4021-8. PubMed ID: 26544652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormone replacement therapy in menopause and risk of breast cancer].
    Clavel-Chapelon F; Hill C
    Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.